Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults

Susanna Esposito, Maria Vincenza Mastrolia, Luciana Ghio, Fabio Paglialonga, Leonardo Terranova, Alessia Scala, Alberto Edefonti, Nicola Principi

Research output: Contribution to journalArticlepeer-review


Aim: To clarify the immunogenicity and safety of influenza vaccine in patients with end-stage kidney disease (ESKD) on dialysis or who have received a kidney transplant. Methods: Sixty adolescents and young adults with ESKD (25 on hemodialysis and 35 kidney transplant recipients) were randomized 1:1 to receive a traditional trivalent split virion vaccine (TIIV) or a virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV). The immunogenicity and safety of the two vaccines was evaluated and compared with the findings observed in 30 healthy subjects of similar age and gender distribution who received TIIV. Results: The results indicate that the immune response of the patients to TIIV and VATIIV were similar. The administered vaccines were safe and well tolerated, and no advantage was found with the use of VATIIV. Conclusion: Given the potential clinical relevance of influenza in patients with ESKD, these findings support the official recommendation that they should receive annual influenza vaccinations.

Original languageEnglish
Pages (from-to)1059-1066
Number of pages8
JournalExpert Review of Vaccines
Issue number8
Publication statusPublished - 2014


  • Chronic renal disease
  • Hemodialysis
  • Influenza vaccination
  • Kidney transplantation
  • Trivalent inactivated influenza vaccine
  • Virosomal-adjuvanted influenza vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine
  • Medicine(all)


Dive into the research topics of 'Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults'. Together they form a unique fingerprint.

Cite this